Skip to main content
Livermore
Livermore
ZHEN

Sofinnova Investments, Inc.

SEC CIK
0001631134
Latest filing
Aug 14, 2026

The latest 13F from Sofinnova Investments, Inc. covers Q2 2026 (filed Aug 14, 2026): 53 long positions worth $1.87B. The top 10 holdings make up 59.8% of the portfolio, and the largest is Natera, Inc. (NTRA) at 22.5%. Livermore has 24 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
11
Est. +$181.3M
Added
12
Est. +$135.9M
Reduced
17
Est. −$397.6M
Sold out
19
Est. −$326.7M

Top 5 holdings

Share of this quarter's portfolio value

  1. NTRANatera, Inc.
    22.5%$420.8MHistory
  2. VERAVera Therapeutics, Inc.
    6.4%$119.9MHistory
  3. GMABGenmab A/S
    5.9%$111.1MHistory
  4. JAZZJazz Pharmaceuticals plc
    4.7%$88.0MHistory
  5. RAPPRapport Therapeutics, Inc.
    4.2%$79.4MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. GMABGenmab A/S
    +$90.5MAddedHistory
  2. SPTXSeaport Therapeutics, Inc.
    +$77.4MNewHistory
  3. GILDGilead Sciences, Inc.
    +$43.3MNewHistory
  4. ANABAnaptysbio, Inc
    +$16.6MAddedHistory
  5. NRIXNurix Therapeutics, Inc.
    +$12.7MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. GMABGenmab A/S
    +4.92 pp1.0% → 5.9%History
  2. SPTXSeaport Therapeutics, Inc.
    +4.14 pp0.0% → 4.1%History
  3. GILDGilead Sciences, Inc.
    +2.32 pp0.0% → 2.3%History
  4. ANABAnaptysbio, Inc
    +1.09 pp0.7% → 1.8%History
  5. MANEVeradermics, Inc
    +0.75 pp0.2% → 1.0%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. AZNAstraZeneca PLC
    −$89.9MSold outHistory
  2. BMYBristol Myers Squibb Co
    −$64.1MReducedHistory
  3. JAZZJazz Pharmaceuticals plc
    −$56.1MReducedHistory
  4. RAREUltragenyx Pharmaceutical Inc.
    −$47.7MReducedHistory
  5. UTHRUnited Therapeutics Corp
    −$45.3MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. AZNAstraZeneca PLC
    −4.51 pp4.5% → 0.0%History
  2. BMYBristol Myers Squibb Co
    −3.34 pp6.0% → 2.7%History
  3. UTHRUnited Therapeutics Corp
    −2.54 pp4.8% → 2.2%History
  4. BIIBBiogen Inc.
    −2.11 pp2.1% → 0.0%History
  5. CELCCelcuity Inc.
    −2.09 pp2.1% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$1.87B
−$123.9M (−6.2%) vs. prior quarter
Positions
53
−8 vs. prior quarter
Top 10 concentration
59.8%
Top 10 as share of value
Turnover
16.4%
Q2 2026, one quarter
Average holding period
11.0 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $2.32B (Q4 2025)

Q1 2021: $1.59BQ2 2021: $1.65BQ3 2021: $1.56BQ4 2021: $1.56BQ1 2022: $1.19BQ2 2022: $1.12BQ3 2022: $1.57BQ4 2022: $1.65BQ1 2023: $1.47BQ2 2023: $1.51BQ3 2023: $1.44BQ4 2023: $1.79BQ1 2024: $1.69BQ2 2024: $1.59BQ3 2024: $1.21BQ4 2024: $1.36BQ1 2025: $1.33BQ2 2025: $1.47BQ3 2025: $1.63BQ4 2025: $2.32BQ1 2026: $2.00BQ2 2026: $1.87B
Q1 2021Q2 2026
13F filings of Sofinnova Investments, Inc. by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202653$1.87BNTRAVERAGMABvs. Q1 2026SEC
Q1 2026May 15, 202661$2.00BNTRABMYJAZZvs. Q4 2025SEC
Q4 2025Feb 13, 202660$2.32BNTRAJAZZAZNvs. Q3 2025SEC
Q3 2025Nov 14, 202555$1.63BNTRAGILDVERAvs. Q2 2025SEC
Q2 2025Aug 14, 202555$1.47BNTRAGILDLLYvs. Q1 2025SEC
Q1 2025May 15, 202559$1.33BNTRASYKVERAvs. Q4 2024SEC
Q4 2024Feb 14, 202560$1.36BNTRAVERAGILDvs. Q3 2024SEC
Q3 2024Nov 13, 202457$1.21BNTRAVERANVOvs. Q2 2024SEC
Q2 2024Aug 9, 202472$1.59BNTRAVERAASNDvs. Q1 2024SEC
Q1 2024Aug 14, 2024Amended67$1.69BNTRAVERAASNDvs. Q4 2023SEC
Q4 2023Aug 15, 2024Amended60$1.79BKRTXRYZBNTRAvs. Q3 2023SEC
Q3 2023Nov 14, 202352$1.44BKRTXNTRAAZNvs. Q2 2023SEC
Q2 2023Aug 14, 202348$1.51BKRTXNTRAAZNvs. Q1 2023SEC
Q1 2023May 11, 202349$1.47BKRTXNTRAMRKvs. Q4 2022SEC
Q4 2022Feb 14, 202346$1.65BKRTXNTRAJBIOvs. Q3 2022SEC
Q3 2022Nov 8, 202251$1.57BKRTXCINCNTRAvs. Q2 2022SEC
Q2 2022Aug 15, 202253$1.12BKRTXNTRACINCvs. Q1 2022SEC
Q1 2022May 16, 202254$1.19BKRTXNTRACINCvs. Q4 2021SEC
Q4 2021Feb 14, 202261$1.56BNTRAKRTXVERAvs. Q3 2021SEC
Q3 2021Nov 15, 202161$1.56BNTRAKRTXASNDvs. Q2 2021SEC
Q2 2021Aug 16, 202161$1.65BNTRAKRTXJBIOvs. Q1 2021SEC
Q1 2021May 14, 202160$1.59BNTRAKRTXBOLT–SEC

13D and 13G filings

Companies where Sofinnova Investments, Inc. reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Sofinnova Investments, Inc. does not currently report owning 5% or more of any company.

Latest filings

4 filings on file made by Sofinnova Investments, Inc. or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Sofinnova Investments, Inc.
CompanyFiled (ET)FormStakeChangeEvent dateFiling
MRNSMarinus Pharmaceuticals, Inc.Feb 12, 20256:40 PM ET13G/A0.00%0 shares–Below 5%Dec 31, 2024SEC
MRNSMarinus Pharmaceuticals, Inc.Nov 14, 202413GOld format–New–SEC
OTICOtonomy, Inc.Feb 14, 202213G/AOld format–––SEC
OTICOtonomy, Inc.Feb 16, 202113GOld format–New–SEC